Nucleai has partnered with Sirona Dx to provide an integrated spatial proteomics solution for pharmaceutical and biotechnology firms for drug development.

Terremoto says that its AKT1 blockers can overcome toxicity challenges associated with PI3K/AKT inhibitors through selective activity.

Boehringer Ingelheim and Zai Lab have entered into a clinical collaboration to investigate a dual DLL3-targeting approach for patients with ES-SCLC and other NECs.

Amazon has already collaborated with Memorial Sloan Kettering Cancer Center with its AI drug discovery software.

Off the back of J&J's positive Q1, CEO Joaquin Duato forecasts strong growth acceleration for 2026, driven partially by psoriasis med Icotyde ...

Adcendo, a clinical-stage biotechnology company developing ADCs for cancer treatment, has raised $75m in a Series C funding round.

Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash.

An analyst noted that this uptick may be a case of “frontloading”, meaning the EU’s 2026 pharma export growth outlook may not be as strong.

Leading pharmaceutical industry players will convene at PHARMAP Congress 2026 on 20-21 April in the Netherlands, bringing together experts from manufacturing and packaging to quality assurance and ...

Travere Therapeutics has received FDA approval for Filspari to reduce proteinuria in patients aged eight years and over with FSGS without nephrotic syndrome.

Italvacuum will present its latest innovations in vacuum-drying technology for the pharmaceutical industry at INTERPHEX Global 2026 (Javits Center, NYC – April 21–23, Booth #3236).

MSD and Daiichi Sankyo have received priority review from the FDA for ifinatamab deruxtecan’s BLA to treat ES-SCLC.